In the News
Global Alzheimer’s Platform Foundation Launches Citizen Scientist Awards®, A National Initiative Celebrating Clinical Trial Participants
Winners to be recognized at UsAgainstAlzheimer’s 2019 National Summit in Washington, D.C. WASHINGTON, D.C. (September 25, 2018) – More than 5.7 million Americans suffer from Alzheimer’s disease and researchers rely upon clinical trial volunteers to be the first step towards a cure. The Global Alzheimer’s Platform Foundation (GAP) has launched the Citizen Scientist Awards®, the first national awards program recognizing and celebrating Alzheimer’s disease clinical […]
Top Alzheimer’s Researchers Hope That Near-100 Dementia Drugs in Trials Are Moving Closer to a Breakthrough
Top Alzheimer’s Researchers Hope That Near-100 Dementia Drugs in Trials Are Moving Closer to a Breakthrough The search for a drug to treat Alzheimer’s disease, the most common form of dementia, has been marked by clinical trial failures. A new report from top researchers says the number of drugs advancing through clinical phase two and […]
How a Raleigh Clinic is Helping Alzheimer’s Patients
Alzheimer’s clinical trial participants are getting a lift to their appointments at Raleigh Neurology Associates. The Global Alzheimer’s Platform Foundation, in partnership with Lyft, is providing transportation to participants in an Eli Lilly study testing a therapy to attack plaque in the brain characteristic of Alzheimer’s disease. Sean Walsh, director of clinical research at Raleigh Neurology Associates, says the new […]
Global Alzheimer’s Platform (GAP) Foundation Launches Partnership with Lyft to Transport Clinical Trial Participants to and from Clinical Research Facilities Across North America
Lyft drivers will transport clinical trial participants to and from GAP-Net research sites WASHINGTON, D.C. (Mar. 20, 2018) – The Global Alzheimer’s Platform Foundation has launched a partnership with Lyft to provide transportation for Alzheimer’s clinical trial participants to and from research sites. The partnership began on Feb. 20 with a pilot in California. Transportation will be available for participants and care partners who […]
Statement from Global Alzheimer’s Platform (GAP) Foundation in Response to Bill Gates’ Investment in Alzheimer’s Research
WASHINGTON, D.C. – “The Global Alzheimer’s Platform Foundation (GAP) enthusiastically welcomes Bill Gates and his team to the fight against Alzheimer’s disease. This epidemic, which affects millions of people worldwide, is growing exponentially and requires new thinking and investment to begin to stem that tide. We at Global Alzheimer’s Platform Foundation are focused on disrupting the Alzheimer’s clinical trial […]
Can GAP double the number of patients in Alzheimer’s trials?
Curing diseases requires new drugs. Getting those new drugs approved by regulators requires data from successful clinical trials. Those trials depend on patients, and right now getting those patients is a challenge for many sponsor companies. According to research performed on recruitment, 85 percent of trials are delayed due to enrollment issues and more than […]
Minority Participation in Clinical Trials can Help Everyone Fight Alzheimer’s
Growing up as an African-American in the South over 75 years ago, my family didn’t have the access to medical care we do today. One event from my childhood changed my life. My mother went to the doctor’s office. She was quite ill and needed help. The doctor said she had to wait to be […]
Global Alzheimer’s Platform (GAP) Foundation Unites 58 of the World’s Leading Research Sites With Goal of Doubling Clinical Trial Participation in USA
More than Half of All National Clinical Trials in Alzheimer’s Take Place at GAP Networked Sites Kansas City Pilot Program Increased Volunteer Trial Participation by 292% WASHINGTON, D.C. (November 1, 2017) – Alzheimer’s disease affects more than 5.4 million Americans and costs taxpayers at least $153 billion dollars per year in Medicare and Medicaid expenses alone. […]
Patient Advocacy Groups Welcome 40% Increase in Alzheimer’s NIH Research Funds Authorized by Congress
The U.S. Congress last week authorized an additional 40 percent in funds for Alzheimer’s disease (AD) research, boosting the fiscal 2017 total by $400 million to nearly $1.4 billion as part of a $2 billion year-over-year increase for the National Institutes of Health (NIH). The final package won praise from the nonprofit Global Alzheimer’s Platform Foundation (GAP), […]
Global Alzheimer’s Platform Foundation Supports $400 Million Congressional Increase for Alzheimer’s Research Funding
Increase is Part of National Institutes of Health (NIH) $2 Billion Funding Boost Bipartisan Support is Good Newsfor 5.5 Million Americans Living with Alzheimer’s and their Caregivers WASHINGTON, D.C. (May 4, 2017) – The Global Alzheimer’s Platform Foundation, a nonprofit organization dedicated to expediting Alzheimer’s clinical trials, applauds today’s $400 million Congressional increase in Alzheimer’s research funding. Under the bipartisan vote, the National […]